FDA Expands Dupilumab Approval to Young Children With Chronic Spontaneous Urticaria

The FDA has approved dupilumab (Dupixent; Sanofi, Regeneron) for the treatment of children aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine (H₁) antihistamine therapy, according to a company announcement. This decision expands the drug’s existing indication in adolescents and adults and establishes dupilumab as the first biologic therapy approved in the US for this younger pediatric population with uncontrolled CSU.¹

CSU is a chronic inflammatory skin condition characterized by recurrent hives, itching, and swelling lasting longer than 6 weeks without a known trigger. The disease can significantly impair quality of life, particularly in young children, where symptoms may disrupt sleep, school, and daily functioning.¹

First Biologic Option for Young Pediatric Patients

The approval marks a notable advancement in CSU management, where treatment options for young children have historically been limited to antihistamines and, in some cases, off-label therapies. Prior to this decision, dupilumab was approved for patients 12 years and older with CSU who remained symptomatic despite standard therapy.^1,2

With this expanded indication, dupilumab is now the first and only biologic therapy specifically approved for children as young as 2 years with uncontrolled CSU in the US. This reflects a broader trend toward earlier intervention with targeted biologic therapies in immune-mediated diseases.^1,2

For pharmacists, the approval introduces a new therapeutic option for a pediatric population with significant unmet need, requiring careful consideration of dosing, administration, and caregiver education.

Clinical Data From LIBERTY-CUPID Program

The FDA’s decision was primarily supported by data from the LIBERTY-CUPID clinical trial program (NCT04180488), which evaluated dupilumab in patients with CSU inadequately controlled by H₁ antihistamines.¹

Although pediatric-specific data were supplemented by extrapolation from adult and adolescent studies, the program demonstrated that dupilumab significantly reduced itch severity and hive activity compared with placebo. These outcomes are particularly relevant in CSU, where symptom burden is often unpredictable and difficult to control with conventional therapy alone.¹

Dupilumab targets IL-4 and IL-13 signaling, key drivers of type 2 inflammation, which is implicated in CSU pathophysiology. This mechanism differentiates it from traditional therapies and supports its role in patients with refractory disease.¹

Safety and Administration Considerations

Dupilumab is administered as a subcutaneous injection, with dosing based on patient weight in pediatric populations. As with other biologics targeting type 2 inflammation, the safety profile is generally consistent with prior indications, although monitoring for hypersensitivity and injection-site reactions remains important.¹

For pharmacists, pediatric biologic therapy introduces additional considerations, including the following:

• Caregiver training on injection technique
• Storage and handling requirements
• Adherence monitoring in a home administration setting
• Coordination with specialty pharmacy services

Pharmacists should also counsel caregivers on expectations for symptom improvement and the importance of continued background therapy, where indicated.

Implications for Pharmacy Practice

The expanded approval has direct implications for pharmacists across community, specialty, and health-system settings. Pharmacists will play a key role in identifying appropriate pediatric candidates with uncontrolled CSU, navigating insurance coverage and prior authorization for biologic therapy, educating caregivers on safe administration and adherence, and monitoring for adverse effects and treatment response.

Additionally, pharmacists can support interdisciplinary care by collaborating with dermatologists, allergists, and pediatricians to optimize therapy selection and follow-up. As biologic therapies continue to expand into pediatric populations, pharmacists will remain essential in ensuring safe, effective, and accessible treatment for complex chronic conditions like CSU.

REFERENCES

1. Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria. News release. Sanofi. April 22, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-21-30-00-3279472

2. Andrus E, Hebebrand M. FDA approves dupilumab for adolescents and adults with H₁ antihistamine-refractory chronic spontaneous urticaria. Dermatology Times. April 18, 2025. Accessed April 23, 2026. https://www.dermatologytimes.com/view/fda-approves-dupilumab-chronic-spontaneous-urticaria